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cJun, a major constituent of AP-1 transcription factor transducing multiple mitogen growth signals, is frequently overexpressed in non-
small cell lung cancers (NSCLCs). The purpose of this study is to determine the effects of AP-1 blockade on the growth of NSCLC
cells using a cJun dominant-negative mutant, TAM67. Transiently transfected TAM67 inhibited AP-1 transcriptional activity in NSCLC
cell lines, NCI-H1299 (H1299), A549 and NCI-H520 (H520). The colony-forming efficiency of H1299 and A549 was reduced by
TAM67, while that of H520 was not. To elucidate the effects of TAM67 on the growth of H1299, we established H1299 clone cells
that expressed TAM67 under the control of a doxycycline-inducible promoter. In the H1299 clone cells, the induced TAM67
inhibited anchorage-dependent growth by promoting G1 cell-cycle block, but not by apoptosis. The induced TAM67 decreased the
expression of a cell-cycle regulatory protein, cyclin A. TAM67 also inhibited anchorage-independent growth of these cells.
Furthermore, TAM67 reduced growth of established xenograft tumours from these cells in nude mice. These results suggest that
AP-1 plays an essential role in the growth of at least some of NSCLC cells.
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c-jun is the cellular homologue of the oncogene v-jun, which was
originally identified as the transforming sequence of avian
sarcoma virus 17 (Bohmann et al, 1987; Maki et al, 1987). cJun
is also a central component of AP-1, which consists of homodimers
and heterodimers of the Jun, Fos and ATF gene family members
and regulates transcription through AP-1 and cAMP responsive
elements (Angel et al, 1987, 1988; Curran and Franza, 1988;
Sassone-Corsi et al, 1990). Many extracellular stimuli rapidly
activate and induce cJun through cytoplasmic signalling cascades
to activate cJun target gene transcription (Karin, 1996; Liu et al,
1996; Whitmarsh and Davis, 1996).
Although the role of cJun in human cancers remains to be
defined, substantial evidence suggests that cJun is involved in
cellular proliferation and transformation. Deregulated expression
of cJun induces immortalised rat fibroblasts to grow in an
anchorage-independent fashion (Schutte et al, 1989) depending on
the induction of multiple cJun target genes (Kinoshita et al, 2003;
Leaner et al, 2003, 2005; Hommura et al, 2004; Katabami et al,
2005). cJun is constitutively expressed in rodent fibroblasts
transformed by activated c-H-ras and raf-1 (Siegfried and Ziff,
1990; Kolch et al, 1993; Osei-Frimpong et al, 1994; Rapp et al,
1994). A dominant-negative mutant of cJun inhibits the
growth and transformation of rodent fibroblasts induced by
c-H-ras, c-raf-1 and even by other various types of oncogenes,
c-mos, c-myc, c-fos and SV40 T antigen (Rapp et al, 1994).
Lung cancer is one of the leading causes of cancer death
throughout the world and its cure rate remains dismally low.
However, molecular biological studies have demonstrated the
existence of multiple genetic and epigenetic alterations of
oncogenes and tumour suppressor genes in the process of lung
carcinogenesis, providing useful information for new therapeutic
strategies. Previous immunohistochemical studies revealed that
cJun is highly expressed in 31–50% of non-small cell lung cancer
(NSCLC) tissues (Wodrich and Volm, 1993; Szabo et al, 1996),
while no immunoreactivity was detected in normal lung counter-
parts. Taken together with its transforming properties, cJun may
have roles in lung carcinogenesis and/or lung cancer growth.
Recently, it has been reported that forced expression of cJun
increases anchorage-independent growth in a human bronchial
epithelial cell line and that constitutive expression of a dominant-
negative mutant of cJun inhibits anchorage-independent but not
anchorage-dependent growth of a lung cancer cell line (Maeno
et al, 2006). These findings suggest rather restrictive roles of cJun
in the acquisition of anchorage independence in the process
of human lung carcinogenesis. In breast and colon cancer cells,
however, inhibition of cJun has been shown to induce G1 cell
arrest on anchorage-dependent conditions (Liu et al, 2004; Suto
et al, 2004). In addition, its effects on in vivo tumour growth of
lung cancer cells have not been investigated. The roles of cJun in
growth remain to be elucidated in lung cancer, when considering
its potential as a therapeutic target.
In the present study, we investigated the effect of a dominant-
negative mutant of cJun, TAM67 (Rapp et al, 1994), on the growth
of NSCLC cells. Transiently transfected TAM67 inhibited colony
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sformation of H1299 and A549 cell lines, two out of the three
NSCLC cell lines tested. Induction of TAM67 under the control of a
tetracycline-inducible promoter suppressed both anchorage-
dependent and -independent growth in H1299 cells by promoting
G1 cell-cycle arrest. Furthermore, the induction of TAM67
significantly decreased in vivo tumour growth of the cells.
MATERIALS AND METHODS
Plasmids
Plasmid pLRT contains all the components of the reverse
tetracycline-regulated (rtTA) system (Tet-on system), a drug-
selectable marker of blasticidin S deaminase as described else-
where (Watsuji et al, 1997). The plasmid pLRT-TAM67 (or -GFP)
was constructed by subcloning TAM67 (or GFP) cDNA from
pGEM-TAM67 (or -GFP) into the parental pLRT vector (Kinoshita
et al, 2003).
Cell lines and culture
The human NSCLC cell lines, H1299, A549 and H520, were
cultured in RPMI 1640 medium supplemented with 10% fetal
bovine serum (FBS) and 0.03% glutamine at 371Ci na n
atmosphere of 5% CO2.
To establish TAM67- and GFP-inducible H1299 clone cells
(H1299 Tet-on TAM67 clone cells and H1299 Tet-on GFP clone
cells), pLRT-TAM67 and -GFP were transfected into packaging
Phoenix A cells by calcium phosphate transfection, and retro-
viruses were harvested after 48h of transfection and infected into
H1299 cells as described elsewhere (Watsuji et al, 1997). Stable
transfectants were selected by blasticidin (Invitrogen, Carlsbad,
CA, USA) at 5mgml
 1 and screened by western blot analysis for
inducibility of TAM67 expression in response to 2mgml
 1
doxycycline.
Luciferase assay
To see the effect of transient expression of TAM67, H1299, A549
and H520 cells were plated in 24-well plates and cotransfected with
0.1mg of TRE2-luciferase plasmid containing two AP-1-binding
sites (Leaner et al, 2003) and either 0.2mg of pCMV-TAM67 or
pCMV control vector using Fugene 6 (Roche Diagnostics, Basel,
Switzerland). To correct for transfection efficiency, 8ng of renilla-
luciferase plasmid was also cotransfected. Transfected cells were
lysed 36h after transfection and luciferase activity was measured
using the Dual-Luciferase Reporter Assay System (Promega,
Madison, WI, USA). To increase AP-1 activity, cells were treated
with 0.1nM 12-O-tetradecanoylphorbol-13-acetate (TPA) for 6h
before harvesting.
To see the effects of induced expression of TAM67, H1299 Tet-
on clone cells were cotransfected with 0.1mg of TRE2-luciferase
plasmid and 8ng of renilla-luciferase plasmid with or without
0.2mgml
 1 doxycycline, and luciferase activity was measured
as described above.
Colony formation assay
The colony formation assay was described previously (Rapp et al,
1994). Briefly, H1299, A549 and H520 cells were plated on 60-mm
plates and cotransfected with 0.3mg of pSV2neo containing a
neomycin-resistant gene and either 2mg of pCMV-TAM67 or
pCMV. Forty-eight hours after transfection, the cells were
trypsinised and equally split into six-well plates. Geneticin
(G418; Sigma, St Louis, MO, USA) was added to a final
concentration of 200mgml
 1. All cells were found to be killed at
this concentration if not transfected with pSV2neo plasmid. After
2 weeks of selection in geneticin, resistant colonies were stained
with crystal violet and counted.
Evaluation of DNA-binding activity of AP-1 by an
enzyme-linked immunosorbent assay
H1299 Tet-on clone cells were cultured in 100-mm plates in the
absence or presence of 2mgml
 1 doxycyclin for a week and then
nuclear extracts were prepared from the cells using the Nuclear
Extract Kit (Active Motif, Carlsbad, CA, USA). The DNA-binding
activity was quantified by enzyme-linked immunosorbent assay
(ELISA) using the TransAM AP-1 family transcription assay kit
(Active Motif) as described previously (Debinski and Gibo, 2005;
Polytarchou et al, 2005). Nuclear extracts were incubated in 96-
well plates coated with immobilised oligonucleotide containing
a consensus-binding site for AP-1 (50-TGAGTCA-30). AP-1 binding
to the target oligonucleotide was detected by incubation with
primary antibodies directed against cJun, JunB, JunD, cFos, FosB,
Fra-1 and Fra-2, visualised with secondary antibody conjugated
with horseradish peroxidase and developing solution, and
quantified by spectrophotometry at 450nm with a reference
wavelength of 655nm. Note that the antibody against cJun
recognises phosphorylated serine 73 of the transactivating domain
of cJun and does not detect TAM67, in which most of the
transactivating domain is deleted. Nuclear extracts from K562 cells
stimulated by TPA were used as a positive control of the assay for
cJun, JunB, JunD, cFos, FosB and Fra-1, and those from WI-38 cells
stimulated by TPA for Fra-2. For the competition analysis, nuclear
extracts were preincubated with the wild-type or mutated AP-1
consensus oligonucleotide.
Western blot analysis
Purified total protein (20mg) was separated by SDS-polyacrylamide
gel electrophoresis, transferred to nitrocellulose membranes
and reacted with rabbit polyclonal anti-cJun antibody (AP-1/Ab-
1; Oncogene Science, Uniondale, NY, USA), rabbit polyclonal
anti-cyclin A antibody (sc-751; Santa Cruz Biotechnology, Santa
Cruz, CA, USA), mouse monoclonal anti-cyclin E antibody (sc-247;
Santa Cruz Biotechnology), mouse monoclonal anti-Kip1/p27
antibody (BD Biosciences, San Jose, CA, USA) and rabbit
polyclonal anti-actin antibody (Sigma). The primary antibody
was detected using anti-rabbit or anti-mouse antibody conjugated
with horseradish peroxidase and visualised using the
Amersham ECL system. Band intensities were quantified by
densitometry.
Cell growth assays
Anchorage-dependent growth of H1299 Tet-on clone cells was
measured in 96-well plates using an MTT (dimethyl thiozolyl-20,
50-diphenylo-2-H-tetrazolium bromide) assay (nonradioactive cell
proliferation assay; Promega) every other day for 7 days in the
absence or presence of 2mgml
 1 doxycycline. To each well was
added 15ml of Dye Solution, and then cells were incubated at 371C.
After 4h, 100ml of Solubilization/Stop Mix solution was added to
each well. One hour later, the contents of the wells were mixed to
yield a uniformly coloured solution. The absorbance at 590nm was
recorded using a 96-well plate reader, and the survival fraction was
quantified. Anchorage-independent growth assays of these cells
were performed using 0.35% soft agarose (Seaplaque; Cambrex,
Rockland, ME, USA) in six-well plates as described previously
(Sabichi et al, 1998). After 2 weeks of incubation in the absence or
presence of 0.1mgml
 1 doxycycline, viable cells were stained by
iodonitrotetrazolium chloride (Sigma) and colony numbers were
counted.
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sCell-cycle analysis
H1299 Tet-on clone cells were cultured in 100-mm plates in the
absence or presence of 2mgml
 1 doxycycline for 4 days. Then,
cells were trypsinised, washed twice with PBS and fixed in 70%
ethanol at  201C. Fixed cells were centrifuged and resuspended in
250mgml
 1 RNase and 50mgml
 1 propidium iodide (Sigma) for
DNA staining. DNA content was measured by a FACS flow
cytometer (BD Biosciences). DNA histograms were obtained using
ModFit LT 2.0 (Verity Software House, Topsham, ME, USA).
Apoptosis assay
H1299 Tet-on clone cells were cultured in 100-mm plates in the
absence or presence of 2mgml
 1 doxycyclin for 4 days. Cells
were trypsinised, washed twice with PBS, fixed in 1% paraformal-
dehyde for 15min on ice and then fixed in 70% ethanol. All cells
were processed using the APO-bromodeoxyuridine staining kit
(Phoenix Flow Systems, San Diego, CA, USA), and subjected to a
flow cytometry-based, modified TdT-mediated dUTP nick end
labelling (TUNEL) assay as described previously (Sueoka et al,
2000). Briefly, the fixed cells were washed and incubated with DNA
labelling solution containing terminal deoxynucleotidyltransferase
reaction buffer, deoxynucleotidyltransferase enzyme and bromo-
deoxyuridine triphosphate (BrdUrd-dUTP). The cells were rinsed
before being resuspended with fluorescein-PRB-1 antibody solu-
tion and analysed by flow cytometry in the presence of propidium
iodide/RNase solution. Analyses of 10000–20000 events were
done with a FACS flow cytometer (BD Biosciences) equipped with
a 488-nm argon ion laser and two software packages: CellQuest 3.1
(BD Biosciences) and ModFit LT 2.0 (Verity Software House). Live
gating of the forward and orthogonal scatter channels was used to
exclude debris and to selectively acquire cell events. A dual display
of DNA area and BrdUrd-dUTP incorporation (FITC-PRB-1) was
used to determine the percentage of propidium iodine-stained cells
that were apoptotic.
Nude mouse xenograft experiments
H1299 Tet-on clone cells (1 10
6 cells) were injected subcuta-
neously into the abdomen of BALB/cA Jcl-nu/nu female mice
(4 weeks old; CLEA Japan, Tokyo, Japan). After tumours developed
and reached the size of 30mm
3, the mice were randomised to
receive doxycycline-containing (200mgml
 1) or doxycycline-free
water. The tumour sizes were measured at intervals of 5 days and
tumour volumes were estimated using the following formula:
length (mm) width (mm) width (mm)/2. To determine induci-
bility of TAM67 expression in tumours, mice were killed 7 days
after the randomisation and local skin tumours were removed.
Protein was extracted from the tumours and subjected to western
blot analysis as described previously (Hakuma et al, 2005). The
animal studies conducted have been approved by the Institutional
Ethical Board for animal welfare at the Hokkaido University
Graduate School of Medicine.
Statistical analysis
All values are presented as mean±s.d. Statistical significance was
determined by Student’s unpaired, two-tailed t-test.
RESULTS
TAM67 inhibits AP-1 activity in NSCLC cells
To determine whether TAM67 inhibits AP-1 activity in NSCLC
cells, H1299, A549 and H520, were cotransfected with TRE2- and
renilla-luciferase vector and either TAM67 expression vector
(pCMV-TAM67) or control vector (pCMV). The transiently
transfected TAM67 inhibited AP-1 activity in these three cell lines
similarly, while basal AP-1 activity in A549 and H1299 was about
four- and fivefold higher, respectively, than that in H520 (Figure 1).
TAM67 also inhibited TPA-induced AP-1 activity in these cells.
These results indicate that TAM67 inhibits AP-1 transcriptional
activity in NSCLC cells.
TAM67 inhibits colony formation of NSCLC cells
We next examined whether TAM67 affects colony-forming
efficiency. H1299, A549 and H520 were cotransfected with
pSV2neo and either pCMV-TAM67 or pCMV. The pSV2neo
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Figure 1 Inhibition of AP-1 transcriptional activity by TAM67 in NSCLC
cells. H1299, A549 and H520 cells were cotransfected with 0.1mg of TRE2-
luciferase plasmid and 8ng of renilla-luciferase plasmid and either 0.2mgo f
pCMV-TAM67 or pCMV control plasmid. Transfected cells were lysed 36h
after transfection and luciferase activity was measured. To increase AP-1
activity, cells were treated with 0.1nM TPA for 6h before harvesting. The
luciferase activity was shown relative to the basal activity in H520
cotransfected with pCMV plasmid without TPA, which was set to 1. Each
value represents the mean±s.d. (n¼3). *Po0.01.
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Figure 2 Colony-forming efficiency of TAM67-transfected NSCLC cells.
H1299, A549 and H520 cells were cotransfected with 0.3mg of pSV2neo
containing a neomycin-resistant gene and either 2mg of pCMV-TAM67
or pCMV. After 2 weeks of selection in geneticin, resistant colonies were
stained with crystal violet. The number of colonies was shown as the
mean±s.d. (n¼3). *Po0.01.
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splasmid but not the pCMV-TAM67 or pCMV plasmid contains a
neomycin-resistant gene to select the transfected cells. As shown in
Figure 2, the colony-forming efficiency of H1299 and A549 was
reduced when these cells were cotransfected with pCMV-TAM67
compared with cells cotransfected with pCMV. On the other hand,
colony formation of H520 was not reduced by pCMV-TAM67.
These results suggest that AP-1 may play an important role in the
growth of H1299 and A549, but not of H520.
Interestingly, some of the colonies of H1299 cells were stained
weakly. The weakly stained colonies contained sparse cells, while
strongly stained ones had piled-up cells (data not shown). The
weakly stained colonies were more prominent in pCMV-TAM67-
cotransfected cells than pCMV-cotransfected cells, suggesting that
AP-1 may be involved in such neoplastic piled-up phenotype
in H1299 cells.
Establishment of H1299 clone cells expressing TAM67
under the control of a doxycycline-inducible promoter
To directly determine the effects of TAM67 on the growth of H1299
cells, we established H1299 clone cells (H1299 Tet-on TAM67 clone
cells and H1299 Tet-on GFP clone cells) that express TAM67 or
GFP under the control of a doxycycline-inducible promoter. We
used a reverse tetracycline-regulated retroviral vector, pLRT-
TAM67, that contains a reverse tetracycline-controlled transacti-
vator, blasticidin S deaminase domain, and TAM67 or GFP under
the control of a tetracycline operator. Stably infected H1299 clone
cells were selected by blasticidin and screened for inducibility of
TAM67 by western blot analysis. We chose two clones, TAM67 #8
and TAM67 #34, because of their highly inducible TAM67
expression in the presence of doxycycline (Figure 3A). As controls,
we used two clones, GFP #1 and GFP #3, which have no inducible
TAM67 expression.
We determined if the induced TAM67 inhibits AP-1 transcrip-
tional activity by a luciferase assay. AP-1 activity was inhibited by
the induction of TAM67 in the presence of doxycycline in TAM67
#8 and TAM67 #34, especially under TPA stimulation (Figure 3B).
On the other hand, AP-1 activity was not affected in GFP #1 and
GFP #3. These results demonstrate that the induction of TAM67
can inhibit AP-1 activity in H1299 cells.
TAM67 affects DNA-binding activity of Jun family
We have investigated whether TAM67 modifies DNA-binding
activity of AP-1 complexes using the ELISA-based TransAM AP-1
family transcription assay kit (Active Motif). The binding of cJun
to AP-1 consensus site was significantly reduced by the induction
of TAM67 (Figure 4A and B). The wild-type AP-1 consensus
oligonucleotide prevented AP-1 binding to the probe immobilised
on the plate, and the mutated consensus oligonucleotide had no
effect on AP-1 binding (Figure 4A), confirming the specificity of
the assay. In H1299 cells, cJun, JunB, JunD and Fra-1 showed high
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Figure 3 Induction of TAM67 using Tet-on system in H1299 cells and its
effect on AP-1 activity. (A) TAM67 expression in H1299 Tet-on TAM67
clone cells (TAM67 #8 and TAM67 #34). The cells were cultured in the
absence or presence of doxycycline for 48h, and the extracted cellular
protein was examined for the TAM67 expression by western blot analysis.
H1299 Tet-on GFP clone cells (GFP #1 and GFP #3) were used as
controls. (B) Inhibition of AP-1 transcriptional activity in H1299 Tet-on
TAM67 clone cells. The cells were cultured in the absence or presence of
doxycycline for a week and were cotransfected with 0.1mg of TRE2-
luciferase plasmid and 8ng of renilla-luciferase plasmid. Transfected cells
were lysed 36h after transfection and luciferase activity was measured. To
increase AP-1 activity, cells were treated with 0.1nM TPA for 6h before
harvesting. Each value represents the mean±s.d. (n¼3). *Po0.01.
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Figure 4 DNA-binding activities of different AP-1 subunits in H1299
cells. H1299 Tet-on clone cells were cultured in the absence or presence of
doxycycline for a week and then the nuclear extracts were prepared.
DNA-binding activity of each AP-1 family member was measured using
TransAM AP-1 kit as described in Materials and Methods. (A) DNA-
binding activity of cJun. The wild-type (Wt) or mutated (Mut) AP-1
consensus oligonucleotide was used as a competitor for cJun binding. Each
value represents the mean±s.d. (n¼3). (B) DNA-binding activities of cJun,
JunB, JunD, cFos, FosB, Fra-1 and Fra-2 (data of p-cJun were replotted from
Figure 4A). Nuclear extract of K562 cells stimulated by TPA was used as
positive control for cJun, JunB, JunD, cFos, FosB or Fra-1 and that of WI-38
cells stimulated by TPA for Fra-2. Each value represents the mean±s.d.
(n¼3). *Po0.01.
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sDNA binding to the AP-1 site, and TAM67 but not GFP
significantly decreased the DNA-binding activities of cJun and
JunD (Figure 4B). These results suggest that TAM67 may inhibit
AP-1 transcriptional activity by modifying the DNA binding of AP-
1 components.
Induction of TAM67 inhibits anchorage-dependent growth
by promoting G1 cell-cycle arrest
We investigated the effects of TAM67 on anchorage-dependent
growth using an MTT assay. The growth of TAM67 #8 and TAM67
#34 was suppressed in the presence of doxycycline, but not in GFP
#1 or GFP #3 (Figure 5A). We next performed flow cytometric
analysis to determine whether TAM67 affects the cell cycle using
TAM67 #8 and GFP #3. The induction of TAM67 by doxycycline
significantly reduced the percentage of cells in S phase, and
increased that in G0/G1 phase in TAM67 #8, while the induction of
GFP did not show such effects in GFP #3 (Figure 5B). We further
examined whether TAM67 induces apoptosis using TUNEL assay
in TAM67 #8. The fraction of DNA fragmentation in the presence
of doxycycline remained low at the same level as that in the
absence of doxycycline (Figure 5C). These results suggest that
TAM67 inhibits cell growth by promoting G1 cell-cycle block in
H1299, but not by apoptosis.
Induction of TAM67 affects the expression of cell-cycle
regulatory proteins
We examined whether the induction of TAM67 affects the
expression of cell-cycle regulatory proteins. As shown in Figure 6,
the induction of TAM67 decreased the expression of cyclin A
approximately in half and increased that of p27 slightly. The
induction of GFP did not show such effects in GFP #1. The
expression of other cell-cycle regulatory proteins, cyclin E, p16 and
p21 was not affected by TAM67 (Figure 6 and data not shown). We
could not detect cyclin D1 in the cell line.
Induction of TAM67 inhibits anchorage-independent
growth in H1299
We determined whether TAM67 inhibits anchorage-independent
growth by soft agar assay. As shown in Figure 7, the growth of
TAM67 #8 and TAM67 #34 was suppressed remarkably in the
presence of doxycycline, but not in GFP #1 and GFP #3. These
results indicate that anchorage-independent growth, as well as
anchorage-dependent growth, is inhibited by TAM67.
TAM67 reduces H1299 xenograft tumours in nude mice
We investigated whether TAM67 could inhibit tumour growth of
H1299 in vivo. TAM67 #8 and GFP #1 were injected subcuta-
neously into nude mice. After tumours developed, the mice were
randomised to receive doxycycline-containing or doxycycline-free
water. TAM67 expression in the tumours derived from TAM67 #8
was induced when the mice received doxycycline-containing water
(Figure 8A). The tumours derived from TAM67 #8 grew fast in the
absence of doxycycline (Figure 8B). In the presence of doxycycline,
however, the tumour growth was significantly reduced. Similarly,
the tumours from GFP #1 grew fast in the absence and presence of
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Figure 5 Cell growth assay, cell-cycle analysis and apoptosis assay. (A) Inhibition of anchorage-dependent growth by the induction of TAM67. H1299
Tet-on clone cells were cultured in the absence or presence of doxycycline for a week and then cell growth was measured using an MTT assay. Each value
represents the mean±s.d. (n¼4). (B) Effects of the induction of TAM67 on cell cycle. H1299 Tet-on clone cells were incubated with 10% FBS in the
absence or presence of doxycyline for 4 days. The percentage of cells in each phase was measured by a FACS flow cytometer and analysed using ModFit LT
software. Each value represents the mean±s.d. (n¼5). *Po0.01. (C) Apoptosis assay under the induction of TAM67. H1299 Tet-on clone cells were
cultured in the absence or presence of doxycycline for 4 days and then apoptosis assay was performed using a flow cytometric analysis as described in
Materials and Methods.
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sdoxycycline. These results demonstrate that TAM67 reduces
growth of established tumours in vivo.
DISCUSSION
The present study demonstrates the suppressive effects of cJun
dominant-negative mutant, TAM67, on both anchorage-dependent
and -independent growth of a NSCLC cell line as well as in vivo
tumour growth. These growth suppressive effects are associated
with G1 cell-cycle arrest, suggesting that at least some of NSCLC
cells depend on AP-1 for growth.
The observed inhibition of AP-1 activity by TAM67 is consistent
with previous reports using various types of cells (Rapp et al, 1994;
Hennigan and Stambrook, 2001; Ludes-Meyers et al, 2001; Suto
et al, 2004). The decreased DNA binding of cJun and JunD to AP-1
consensus sequence by TAM67 suggests that TAM67 may compete
with and replace the proteins in AP-1 complexes to decrease AP-1
activity. On the other hand, TAM67 has been shown to have
similar DNA-binding affinity to cJun and to inhibit AP-1 activity
through a ‘quenching’ mechanism by inhibiting endogenous Jun
and/or Fos proteins (Brown et al, 1994). Therefore, there is also the
possibility that TAM67 quenches other AP-1 components includ-
ing Fos proteins.
The colony-forming assay and the subsequent MTT assay
demonstrated that the AP-1 blockade by TAM67 inhibits
anchorage-dependent growth of H1299 NSCLC cells. The use of
multiple TAM67- and GFP-inducible clone cells minimises the
possibility of clonal variations and nonspecific effects of doxycy-
cline. Similar effects of AP-1 blockade on growth suppression have
been shown in one out of four breast cancer cell lines and in a
colon cancer cell line (Ludes-Meyers et al, 2001; Suto et al, 2004).
Taken together, it is suggested that some of cancer cells, including
NSCLC cells, depend on AP-1 for anchorage-dependent growth.
Although TAM67 could induce G1 cell-cycle arrest and
apoptosis, the results of the apoptosis assay and the observed
increase in G1 phase without sub-G1-phase fraction after the
induction of TAM67 suggest that the main mechanism of the
growth inhibition by the AP-1 blockade is G1 cell-cycle arrest. In
fibroblasts, microinjection of antibodies against Jun or Fos
proteins blocks entrance into the S phase (Kovary and Bravo,
1991). In a human fibrosarcoma cell line, TAM67 inhibits AP-1
activity and arrests cells predominately in the G1 phase of the cell
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Figure 6 Effects of the induction of TAM67 on the expression of cell-
cycle regulatory proteins. H1299 Tet-on clone cells were incubated with
10% FBS in the absence or presence of doxycyline for 4 days. The
extracted protein (20mg) was analysed for cyclin A, cyclin E and p27
expression by western blot analysis as described in Materials and Methods.
To normalise the total protein quantity in each sample, the band intensities
of cyclin A, cyclin E and p27 were divided by those of actin in the same
sample. The expression levels were normalised to those in the absence of
doxycycline. Each value represents the mean±s.d. (n¼5).
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Figure 8 Tumour growth inhibition under the induction of TAM67 in
nude mice. H1299 Tet-on clone cells were injected subcutaneously into
BALB/c nude mice. After tumours developed and reached the size of
30mm
3, the mice were randomised to receive doxycycline-containing or
doxycycline-free water. (A) Induction of TAM67 expression in established
tumours from TAM67 #8 cells. Mice were killed 7 days after the
randomisation and local skin tumours were removed. The extracted
tumour protein (20mg) was analysed for TAM67 expression by western
blot analysis. (B) The tumour sizes were measured at intervals of 5 days
and tumour volumes were estimated as described in Materials and
Methods. Each value represents the mean±s.d. (n¼5). *Po0.01.
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scycle (Hennigan and Stambrook, 2001). AP-1 blockade in breast
cancer cells induces G1 cell-cycle block, which is associated with
decreases in G1 cyclin expression and cyclin-dependent kinase
activity (Liu et al, 2004). Moreover, TAM67 inhibits entrance into
the S phase after serum stimulation in colon cancer cells (Suto
et al, 2004). Taken together, AP-1 blockade inhibits growth by
promoting G1 cell-cycle block in various types of malignant cells.
In the present study, we demonstrated that the induction of
TAM67 reduce the expression of a cell-cycle regulatory protein,
cyclin A. Cyclin A can function during both G1/S and G2/M phases
of the cell cycle (Girard et al, 1991; Pagano et al, 1992; Resnitzky
et al, 1995). We have previously shown that cyclin A is a direct
cJun-target gene in immortalised rat fibroblasts and is necessary
for cJun-induced anchorage-independent growth (Katabami et al,
2005). The downregulation of cyclin A may also be involved in the
mechanisms of G1 cell-cycle arrest induced by AP-1 blockade in
H1299 NSCLC cells.
Anchorage-independent growth is a hallmark of cancer and is
associated with in vivo tumour growth. Suppression of the
anchorage-independent growth of H1299 NSCLC cells by AP-1
blockade is consistent with previous reports using another NSCLC
cell line (Maeno et al, 2006). Furthermore, we demonstrate that
in vivo tumour growth of the NSCLC cells is also suppressed by
AP-1 blockade. In vivo tumour growth suppression by AP-1
blockade has also been shown in breast and colon cancer cells (Liu
et al, 2002; Suto et al, 2004). These results suggest that the
blockade of AP-1 could be a useful strategy for the treatment of
cancers, including NSCLCs.
It has been recently demonstrated that forced expression of cJun
increases anchorage-dependent growth in a human bronchial
epithelial cell line and that constitutive expression of a dominant-
negative mutant of cJun inhibits anchorage-independent but not
anchorage-dependent growth of a lung cancer cell line (Maeno
et al, 2006). Although these findings suggest roles of cJun in the
anchorage independence in the process of carcinogenesis, it does
not necessarily suggest that cJun is irrelevant to anchorage-
dependent growth of NSCLCs. In breast cancer, anchorage-
dependent growth is suppressed in one out of four cell lines
(Ludes-Meyers et al, 2001). In the present study, two cell lines but
not the other depend on AP-1 for their anchorage-dependent
growth. Therefore, roles of AP-1 in the growth seem to differ
among cancer types and even among cell lines in a specific type of
cancer.
Different sensitivities to AP-1 blockade by TAM67 among
H1299, A549 and H520 may reflect the difference in their basal AP-
1 activity. Despite similar suppression of AP-1 activity by TAM67
in these cell lines, the basal activity was higher in H1299 and A549
than in H520, suggesting that the cells with high basal AP-1 activity
may be more dependent on AP-1 for their growth. In addition, the
compositions of AP-1 dimers may affect the TAM67 sensitivity.
Although all three cell lines have high cJun expression, expressions
of other components are different; H1299 has high expressions of
JunB, JunD, cFos and Fra-1, and A549 has those of cFos and JunD
while H520 has minimal or no expression of these genes (Szabo
et al, 1996). A recent study using several TAM67 mutants that have
different binding specificities to AP-1 components indicates that
TAM67 likely inactivates Fos family member proteins to suppress
cell growth of breast cancer (Lu et al, 2005). These results suggest
that the basal activity and compositions of AP-1 in cancer cells
may affect growth inhibition by TAM67.
In conclusion, we demonstrated that the blockade of AP-1
transcriptional activity by a dominant-negative cJun mutant
suppresses NSCLC cells growth both in vitro and in vivo. These
results suggest that AP-1 plays an essential role in the growth of
at least some of NSCLC cells.
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